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Introduction 
The United Kingdom (UK)voted in a referendum in June 2016 to leave the European 
Union  (EU) after 45 years of  membership. Among the many political , social and 
scientific consequences are those for the regulation of  health care products. No longer 
will the efficacy, safety and quality of   medicines in the UK be subject to a EU regulatory 
framework. The European Medicines Agency ( EMA) currently located in London , will 
move elsewhere in Europe. The pharmaceutical industry will reassess its commitment to 
the UK health scene. 
(75 words) 
In the UK, the regulation of  medicines takes place almost entirely through the incorporation 
into UK law of  a series of  European directives, through what is now the Medicines Regulations 
2012 In addition to being regulated by EU-wide laws, the European regulatory framework for 
medicinal products has evolved to facilitate the collation of  post-marketing efficacy and 
pharmacovigilance safety metadata across the EU. The European Medicines Agency (EMA), 
based in Canary Wharf  in London, is ultimately responsible for good pharmacovigilance 
practice, and for the evaluation of  the causation of  safety-related events across Europe. It has 
developed the necessary infrastructure and expertise for the rapid evaluation of  post-licensing 
safety and efficacy data from the 28 countries within the EU, and another three in the European 
Economic Area (EEA). This enables it to identify and act upon any changes to the risk-benefit 
profiles of  new medicines in a robust and timely manner. The EMA has also acquired the 
necessary expertise to issue marketing authorisations for more complex new medicinal products, 
for cancer and orphan indications, for example. Decoupling the UK’s regulatory system from 
that of  the EMA would be likely to cause delays and additional costs for manufacturers seeking 
to market innovative products in the UK, which in turn could result in slower access for patients 
and increased costs for the NHS. 
As an agency of  the EU, the EMA will almost certainly have to relocate when the UK leaves the 
EU, and there is currently a bidding war among several European nations keen to host an agency 
that brings jobs, expertise and benefits for the domestic healthcare system. Anders Lönnberg, 
the Swedish government’s life sciences coordinator, explained to The Times why Sweden is keen 
to inherit the EMA from the UK: ‘We get 900 jobs and a network of  highly skilled researchers. It 
will help a lot with national healthcare’. Loss of  the EMA is also likely to affect future 
pharmaceutical investment in the UK. As a statement released by the Japanese Ministry of  
Foreign Affairs has explained: ‘If  the EMA were to transfer to other EU member states, the 
appeal of  London as an environment for the development of  pharmaceuticals would be lost, 
which could possibly lead to a shift in the flow of  R&D funds and personnel to continental 
Europe’. 
In addition to losing the EMA, leaving the EU will mean that the UK will no longer 
automatically comply with amendments to the European Medicines Directive and ancillary 
European legislation regarding, for example, clinical trials and pharmacovigilance.  It is also 
unclear whether European consumer protection legislation such as the Products Liability 
Directive and General Products Safety Directive will remain enshrined in UK law. Even if  
existing medicines regulations are consolidated into UK law when the UK leaves the EU, they 
would no longer be subject to automatic updates as EU law adapts to the changing landscape of  
medicines regulation. 
It could be argued that changes in the development of  innovative medicinal products make this 
an especially unpropitious time to depart from an effective, pan-European regulatory framework. 
The taxonomy of  disease is changing in order to define pathologies, like cancer, based on 
molecular mechanisms, rather than target tissues. As new medicines become more precise and 
personalised, their target markets shrink. Coupled with the public health imperative to accelerate 
approval regimes for innovative therapies, it is increasingly possible – through mechanisms such 
as conditional licensing schemes – for innovative medicines to enter the market at earlier stages 
in their development, in the absence of  large-scale clinical trial data. Innovative licensing 
schemes for new medicines necessitate the initial evaluation of  risk-benefit profiles on the basis 
of  much smaller clinical trial data. With smaller clinical trials, the rigorous collection, monitoring 
and evaluation of  post-licensing safety and efficacy data becomes ever more important. Similarly, 
for medicines for rare diseases, designated for orphan indication status, composite clinical studies 
carried out throughout Europe are needed in order to maximise statistical power when safety 
and efficacy data are evaluated at increasingly early stages of  a new drug’s clinical development. 
The safety of  medicines within the UK is enhanced by its membership of  an EU-wide 
regulatory framework. Drug development throughout the EU benefits from the infrastructure 
and scientific resources and expertise in the EMA, and in other member states. Leaving this 
regulatory framework will certainly not enhance the UK’s capacity to evaluate robustly the risk-
benefit profiles of  new medicines. To the contrary, there is a real danger of  a reduced ability to 
detect safety signals in new medicines, especially in the immediate post-launch period when the 
first evidence of  as yet undetected safety risks might be likely to emerge. Given the profile of  
many new and increasingly specialised medicines, any reduction in the effectiveness of  the UK’s 
pharmacovigilance regime is to be lamented, on public health grounds 
THERE  ARE ALSO REGULATORY CONSEQUENCES OF BREXIT FOR THE EMA 
AND THE EU. THE UK REGULATORY AUTHORITY , THE MEDICINES AND 
HEALTHCARE PRODUCTS REGULATORY AGENCY (MHRA) CURRENTLY 
SHOULDERS A SUBSTANTIAL PROPORTION OF THE WORK OF THE EMA. SOME 
30% OF THE APPLICATIONS FOR EUROPEAN MARKETING AUTHORISATIONS 
ARE ASSESSED BY THE MHRA; UK PLAYED AN IMPORTANT ROLE IN THE 
F O R M U L A T I O N O F B O T H T H E E U R O P E A N C L I N I C A L T R I A L S 
REGULATIONS(2014) AND THE EUROPEAN PHARMACOVIGILANCE 
REGULATIONS (2012). FURTHER,  SEVERAL OF THE COMMITTEES OF THE EMA 
ARE CHAIRED BY UK REPRESENTATIVES. DECOUPLING THE MHRA FROM THE 
EMA WILL RESULT IN A LOSS OF THE PRAGMATISM, EXPERTISE  AND 
RESOURCE OF THE MHRA. A FUTURE EMA WITHOUT THE MHRA WILL NOT BE 
AS STRONG. IN CURRENT PARLANCE! THIS HAS THE APPEARANCE OF A  'LOSE-
LOSE' SITUATION. 
As far as we are aware, there has been little discussion of  the public health consequences of  this 
particular implication of  Brexit. The dangers would be minimised if  the UK continued to be 
part of  the single market, as a result of  joining Iceland, Liechtenstein and Norway in the 
European Economic Area, but the price of  membership of  the EEA is freedom of  movement. 
Outside of  the single market, the UK might try to negotiate an exit from the EU which retains 
the supremacy of  European medicines regulations and directives, and therefore access to the 
centralised procedure for marketing authorisations and the pharmacovigilance infrastructure. But 
whether it would be possible to secure the ongoing primacy of  European law in one area of  
business remains open to question. Cross-European pharmaceutical legislation celebrated its 50th 
anniversary in 2015, and the EMA now serves a population of  more than 500 million EU 
citizens. In the context of  increasingly specialised new medicinal products, subject to innovative 
early-licensing schemes, there is strength in numbers, and, conversely, a serious risk to public 
health from isolationism. 
748 words 
The authors declare no conflicts of  interest 
All authors contributed to the text of  the article 
